Want to join the conversation?
$REGN said that for full-year 2016 it expects EYLEA US net product sales to be up 20-25% over 2015. Sanofi reimbursement of Regeneron commercialization-related expenses are expected to be $310-340MM in 2016, down from the previous range of $320-370MM. CapEx is expected to be in the range of $480-530MM, down from the previous range of $550-625MM.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.